According to filings with the U.S. Securities and Exchange Commission, Antogen Inc. has raised in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: iGrow Venture Partners.

About Antogen Inc.
Antogen is pioneering a new class of research tools and diagnostics to transform patient care and health outcomes. The company is led by an experienced team of life sciences innovators and backed by a syndicate of supportive investors. Antogen provides immunopeptidomics services to identify and quantify peptideHLA ligands directly from biological samples supporting discovery programs and translational studies in oncology, immunotherapy development, and autoimmune disease research. Antogen has prepared a comprehensive immunopeptidome library to reduce or eliminate off-target risks and accelerate candidate selection.

To learn more, visit https://antogen.com/
Linkedin: https://www.linkedin.com/company/antogen/

Contact:
Zachary Antovich, Chief Executive Officer
https://www.linkedin.com/in/zachary-antovich-321a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.